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63018F-FDG Imaging in
Patients With
“Suspected,” But Not
“Proven,” SarcoidosisIn a recent issue of the Journal, Blankstein et al.
(1) examined clinical outcomes in 118 patients
with known or suspected cardiac sarcoidosis who
were referred for positron emission tomography
(PET) evaluation. Patients with both perfusion de-
fects and focal increased 18F-ﬂuorodeoxyglucose (18F-
FDG) uptake had an almost 4-fold increased risk of
adverse events (sustained ventricular tachycardia or
death). The authors propose that these ﬁndings offer
prognostic value beyond the revised Japanese Min-
istry of Health (JMWH) criteria (2), the presence of
extracardiac sarcoidosis, and left ventricular ejection
fraction. We commend the investigators for address-
ing this understudied subject. However, we would
like to raise concerns that make us hesitant to accept
the main conclusion as it relates to patients with
cardiac sarcoidosis.
The presented patient population almost certainly
includes other cardiomyopathies (e.g., myocarditis)
that should be excluded before considering the
diagnosis of sarcoidosis. Cardiac magnetic resonance
imaging (available for 39 patients) should provide
additional diagnostic accuracy. In the absence of
histological evidence of myocardial involvement,
the revised JMWH criteria (2) require deﬁnite evi-
dence of extracardiac involvement based on histol-
ogy or a combination of stringent clinical criteria.
Only 28 (24%) patients in the study (1) had histo-
logical evidence of extracardiac sarcoidosis, and 38
(34%) met the JMWH criteria. Furthermore, the
event rate in the study is substantially higher than
the event rates reported (both in primary and sec-
ondary prevention) in patients with actual cardiac
sarcoidosis (3–6). Based on these differences, one
may wonder whether the data provided in this study
are actually applicable to patients with sarcoidosis.
Another possibility to explain the low prevalence of
extracardiac sarcoidosis would be the presence of
isolated cardiac sarcoidosis. Do the authors presume
that this entity was particularly prevalent in their
cohort?
With respect to the prognostic value of 18F-FDG
PET, a major concern is the failure to exclude patients
with episodes of sustained ventricular tachycardia
(VT). Twenty-four patients (21%) had a known history
of VT, and 48 (41%) had implantable cardioverter-deﬁbrillators (ICDs) before the PET study. Secondary
prevention patients are known to be at high risk for
future arrhythmic events necessitating ICD implan-
tation. The annualized rates of appropriate therapies
in secondary prevention patients in recent papers
were between 14% (3) and 21% (4,5). In the Blankstein
et al. paper (1), among the 31 patients with adverse
events, 24 (77%) had an ICD implanted before the PET
study. The failure of the univariate analysis to show a
statistically signiﬁcant difference in the hazard ratio
between patients with and without prior sustained
VT is likely due to low sample size, rather than a
genuine lack of difference. Only 4 patients in the
current study group received an ICD after a PET study
was performed and presented adverse outcomes. The
provided data show an association between an
abnormal PET study and adverse events, but fail to
demonstrate a convincing contribution of PET to
identifying patients who beneﬁt from ICD implanta-
tion. In this regard, it is particularly unsettling that a
substantial number of patients with normal PET
studies had adverse events. This puts the potential
role of 18F-FDG PET for risk stratiﬁcation into ques-
tion. The actual role of 18F-FDG imaging in patients
with “suspected,” but not proven, sarcoidosis is not
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